Last $0.52 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

boston therapeutics inc (BTHE) Snapshot

Open
$0.52
Previous Close
$0.52
Day High
$0.52
Day Low
$0.52
52 Week High
01/3/14 - $1.67
52 Week Low
08/15/13 - $0.15
Market Cap
20.0M
Average Volume 10 Days
14.6K
EPS TTM
--
Shares Outstanding
38.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON THERAPEUTICS INC (BTHE)

Related News

No related news articles were found.

boston therapeutics inc (BTHE) Related Businessweek News

No Related Businessweek News Found

boston therapeutics inc (BTHE) Details

Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in veterinary medicine applications. Boston Therapeutics, Inc. was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. The company was founded in 2009 and is headquartered in Manchester, New Hampshire.

8 Employees
Last Reported Date: 04/10/14
Founded in 2009

boston therapeutics inc (BTHE) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $71.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $68.1K
Compensation as of Fiscal Year 2013.

boston therapeutics inc (BTHE) Key Developments

Boston Therapeutics, Inc. Appoints Zbigniew J. Witczak to its Scientific Advisory Board

Boston Therapeutics, Inc. announced that it has appointed Zbigniew J. Witczak, Ph.D. to its Scientific Advisory Board (SAB). Dr. Witczak is professor and chair of the Department of Pharmaceutical Sciences at Wilkes University in Wilkes-Barre, Pennsylvania, and has taught Principles of Bioorganic and Medicinal Chemistry at the Nesbitt School of Pharmacy at Wilkes University for the past 14 years.

Boston Therapeutics, Inc. Appoints Benjamin Rivnay as Chief Scientist

Boston Therapeutics, Inc. has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the company's science and technology. He will serve as the primary liaison to the company's Medical Advisory Board and report to Rom E. Eliaz, Ph.D., chairman of the board of directors Scientific Advisory Committee. Dr. Rivnay is a seasoned director of technology and research activities within the biotechnology industry. Most recently, he was Director of Research and Development at Formatech Inc.

Kenneth A. Tassey, Jr. Resigns as President and Director of Boston Therapeutics, Inc

Effective as of June 30, 2014, Kenneth A. Tassey, Jr. resigned as President and a director of Boston Therapeutics, Inc. Mr. Tassey's resignation was not the result of any disagreements with the company regarding its operations, policies, or practices.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTHE:US $0.52 USD 0.00

BTHE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTHE.
View Industry Companies
 

Industry Analysis

BTHE

Industry Average

Valuation BTHE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 56.6x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON THERAPEUTICS INC, please visit www.bostonti.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.